TABLE 1.
Baseline variables.
| Variables | Study patients n = 75 | Data available (n) |
|---|---|---|
| Variables recorded at the time of transplantation | ||
| Recipient age, median (IQR) | 45 (34.5–53.5) | 75 |
| Female sex, n (%) | 37 (49.3) | 75 |
| Deceased donor, n (%) | 63 (84.0) | 75 |
| Living donor, n (%) | 12 (16.0) | 75 |
| Donor age (years), median (IQR) | 46 (26–58) | 73 |
| Prior kidney transplant, n (%) | 27 (37.0) | 73 |
| Current CDC panel reactivity ≥10%, n (%) | 15 (21.4) | 70 |
| Preformed anti-HLA DSA, n (%) a | 25 (62.5) | 40 |
| Cold ischemia time (hours), median (IQR) | 12 (8.1–17.1) | 71 |
| HLA mismatch (A, B, DR), median (IQR) | 3 (2–4) | 73 |
| HLA mismatch (A, B, C, DRB1, DQB1), median (IQR) | 5 (4–6) | 58 |
| Initial immunosuppression | 75 | |
| Induction with anti-thymocyte globulin, n (%) | 31 (41.3) | 75 |
| Induction with IL-2 receptor antibody, n (%) | 19 (25.3) | 75 |
| Tacrolimus-based immunosuppression, n (%) | 44 (58.7) | 75 |
| Cyclosporine A-based immunosuppression, n (%) | 29 (38.7) | 75 |
| mTOR inhibitor-based immunosuppression, n (%) | 5 (6.7) | 75 |
| Peri-transplant immunoadsorption, n (%) | 27 (36) | 75 |
| Variables recorded at the time of index biopsy | ||
| Years after transplantation, median (IQR) | 5.17 (2.41–13.21) | 75 |
| Renal parameters | ||
| eGFR (mL/min/1.73 m2), median (IQR) | 39.9 (26.7–59.6) | 75 |
| UPCR (mg/g), median (IQR) | 373 (134–1252) | 75 |
| UPCR >1,000 mg/g, n (%) | 23 (30.7) | 75 |
| Immunosuppression at the time of index biopsy | ||
| Triple immunosuppression (%) | 60 (80.0) | 75 |
| Tacrolimus, n (%) | 51 (68.0) | 75 |
| Cyclosporine A, n (%) | 20 (26.7) | 75 |
| mTOR inhibitor, n (%) | 3 (4.0) | 75 |
| Belatacept, n (%) | 1 (1.3) | 75 |
| Anti-rejection therapy triggered by ABMR diagnosis, n (%) | 42 (56.0) | 75 |
| Bortezomib | 20 (26.7) | 75 |
| Clazakizumab | 15 (20.0) | 75 |
| BIVV009 | 9 (12.0) | 75 |
| Tocilizumab | 2 (2.7) | 75 |
| Imlifidase/IVIG/rituximab | 1 (1.3) | 75 |
| Immunoadsorption | 1 (1.3) | 75 |
DSA, donor-specific antibody; CDC, complement-dependent cytotoxicity; eGFR, estimated glomerular filtration rate; IQR, interquartile range; mTOR, mammalian target of rapamycin; UPCR, urinary protein/creatinine ratio.
a
For recipients transplanted before 2009, solid-phase HLA antibody screening on the transplant wait list was not available.